QMSR Is No Longer a Future Deadline: What FDA Inspection Readiness Looks Like Now

For the last two years, many medical device manufacturers talked about QMSR as a coming transition. That transition has arrived.

FDA's Quality Management System Regulation became effective on February 2, 2026. The agency has stated that it will enforce the QMSR requirements and use a new inspection process aligned to the updated regulation. For manufacturers, that means QMSR readiness can no longer live in a project plan, a gap assessment, or a training slide deck. It has to show up in daily quality system execution.

The practical question is no longer, "Have we updated our procedures?"

The better question is, "Can we show that our system is operating in a controlled, connected, and inspection-ready way?"

QMSR readiness is more than ISO 13485 alignment

The QMSR incorporates ISO 13485:2016 by reference, but that does not mean FDA inspections have become the same as a certification audit. FDA has been clear that it does not issue ISO 13485 certificates, does not require ISO 13485 certification, and will continue to inspect medical device manufacturers based on FDA requirements.

That distinction matters. A manufacturer may have an ISO 13485 certificate and still struggle during an FDA inspection if records are fragmented, quality issues are not trended, supplier controls are weak, or management review does not show meaningful oversight.

QMSR readiness is not simply a clause-by-clause mapping exercise. It is an operational discipline. The system has to demonstrate that quality processes are defined, implemented, connected, and producing reliable evidence.

The records FDA can review deserve immediate attention

One of the most important practical shifts is record availability. Under the QMSR, FDA has authority to inspect management review, quality audit, and supplier audit reports. The prior QS Regulation exceptions for those categories were not maintained.

That does not mean every inspection will look the same. It does mean manufacturers should assume that records traditionally treated as internal quality documents may be requested and should be maintained in a state that is accurate, complete, and ready for review.

This creates a real burden for quality teams. Internal audits, supplier audits, and management review records often contain the clearest evidence of whether leadership knows the state of the quality system. If those records are scattered across shared drives, slide decks, email threads, and spreadsheets, inspection response becomes slower and riskier.

Manufacturers should review whether these records clearly show:

• The scope and frequency of internal audits
• Objective evidence reviewed during supplier audits
• Quality trends escalated to leadership
• CAPA effectiveness and recurring issue analysis
• Resource decisions tied to quality risk
• Follow-through on management review outputs

A record that technically exists but cannot be produced, explained, or connected to follow-up action is not strong inspection evidence.

CAPA and risk management are where disconnected systems are exposed

QMSR inspections are likely to continue focusing on the practical health of the quality system. CAPA, complaints, nonconforming product, design changes, supplier issues, and post-market signals are rarely isolated. They are connected indicators of how well the organization identifies, evaluates, and controls risk.

For manufacturers, the challenge is that many quality systems are not built around that connection. A complaint may live in one tracker, a risk file in another system, a design change in a PLM tool, a supplier investigation in email, and CAPA evidence in a document repository. Each individual artifact may be acceptable, but the inspection story becomes difficult to tell.

The risk is not only administrative. Disconnected systems can delay escalation, weaken root cause analysis, and make recurring issues harder to identify. If a supplier nonconformance has design, manufacturing, and post-market implications, the quality system should make that relationship visible.

Manufacturers should test their readiness by walking through real scenarios:

• A recurring complaint trend that triggers a CAPA
• A supplier failure that affects released product
• A design change that updates risk controls and labeling
• A process deviation that requires retraining and effectiveness checks
• A post-market signal that leads to management review discussion

If the evidence trail requires multiple manual searches, tribal knowledge, and cross-functional reconstruction, the system is not inspection-ready enough.

Management review needs to become an active control point

Under QMSR, management review should not be treated as a quarterly meeting to satisfy a calendar requirement. It is a governance mechanism. Leadership needs visibility into whether the quality system is effective, whether risks are increasing, and whether resources are sufficient.

The best management review records do more than summarize metrics. They show decisions. They connect inputs to actions. They make it clear when leadership accepted, escalated, funded, or redirected work based on quality evidence.

Manufacturers should ask whether management review records answer these questions:

• What changed in the risk profile of our products or processes?
• Which quality issues are recurring?
• Which suppliers are creating systemic burden?
• Are CAPAs being closed effectively or just administratively?
• Are audit findings being reduced, repeated, or deferred?
• What resource decisions were made because of the data?

When management review is reduced to a slide deck, it becomes difficult to show that leadership is actively controlling the quality system. When it is connected to CAPA, supplier quality, risk management, audits, training, and post-market surveillance, it becomes a powerful inspection readiness asset.

What manufacturers should do now

The most effective next step is not another broad policy rewrite. Most companies have already done some level of QMSR procedure update. The higher-value work is to pressure-test whether the system can produce complete, connected, and current evidence.

Manufacturers should prioritize five actions:

1. Run a QMSR evidence walk-through using actual records, not templates.
2. Confirm that internal audit, supplier audit, and management review records are controlled and readily retrievable.
3. Map high-risk workflows across CAPA, complaints, design changes, supplier quality, and risk management.
4. Review whether training records show effective implementation of revised procedures.
5. Use management review to evaluate QMSR readiness as an active business risk.

The companies that will be strongest under QMSR are not necessarily the ones with the longest quality manuals. They are the ones that can show how their system works.

How IntelaSolve helps

IntelaSolve was built for this kind of connected compliance burden. Medical device and diagnostics manufacturers need more than a document repository. They need compliance infrastructure that links regulatory strategy, design control, risk management, supplier quality, CAPA, quality operations, manufacturing, and post-market surveillance across the product lifecycle.

With IntelaSolve, teams can move away from point-solution stacks, disconnected spreadsheets, and manual evidence reconstruction. The goal is not to promise an inspection outcome. The goal is to give manufacturers a clearer, more reliable operating model for producing audit-ready evidence from the way work is actually performed.

QMSR is now the operating reality. The manufacturers that treat it as a connected quality system challenge, not a one-time documentation update, will be better prepared for the next inspection and better positioned to scale.

Preparing for a QMSR inspection? Request an IntelaSolve Compliance Readiness Analysis to see where your quality system evidence is strong, where it is fragmented, and what should be connected before your next FDA inspection.